NCT06351020View on ClinicalTrials.gov

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

PHASE3RecruitingINTERVENTIONAL
Enrollment

375

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

November 10, 2026

Study Completion Date

December 15, 2026

Conditions
Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
Interventions
DRUG

LM-302

LM-302 intravenous-injection every 2 weeks on Day 1 of each 14-day cycle

DRUG

Apatinib

The subjects will receive Apatinib orally,qd

DRUG

Irinotecan

The subjects will receive Irinotecan intravenous-injection,every 2 weeks on Day 1 of each 14-day cycle

Trial Locations (2)

100000

RECRUITING

Peking Union Medical College Hospital, Beijing

200000

RECRUITING

Shanghai East Hospital, Shanghai

All Listed Sponsors
lead

LaNova Medicines Zhejiang Co., Ltd.

INDUSTRY